Advertisement
Advertisement
STLN
Starling Oncology, Inc. Common Stock
4.34
USDSponsored
+0.34
+8.50%
Nov 10, 15:59 UTC -5
Closed
After-Market
4.45
+0.11
+2.42%
Starling Oncology, Inc. Common Stock (STLN) Earnings
STLN Earnings Reports
Positive Surprise Ratio
STLN beat 1 of 3 last estimates.
33%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$184.83M
/$0.00
Implied change from Q3 26 (Revenue/ EPS)
+8.87%
/-100.00%
Implied change from Q4 25 (Revenue/ EPS)
--
/-100.00%
Starling Oncology, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, STLN reported earnings of -0.13 USD per share (EPS) for Q3 26, missing the estimate of -0.05 USD, resulting in a -154.90% surprise. Revenue reached 169.77 million, compared to an expected 172.06 million, with a -1.33% difference. The market reacted with a -45.97% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.00 USD, with revenue projected to reach 184.83 million USD, implying an decrease of -100.00% EPS, and increase of 8.87% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Starling Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Starling Oncology, Inc. Common Stock reported EPS of -$0.13, missing estimates by -154.9%, and revenue of $169.77M, -1.33% below expectations.
How did the market react to Starling Oncology, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -45.97%, changed from $6.70 before the earnings release to $3.62 the day after.
When is Starling Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Starling Oncology, Inc. Common Stock's next earnings report?
Based on --
analysts, Starling Oncology, Inc. Common Stock is expected to report EPS of -- and revenue of $184.83M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.